ENDRA Life Sciences Inc. (NDRA) Bundle
Ever wondered about the company pioneering a new way to visualize tissue, potentially revolutionizing medical diagnostics? ENDRA Life Sciences Inc. (NDRA) is making waves with its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, but how exactly does it work, and what's their mission? Dive in to discover how ENDRA aims to provide a cost-effective alternative to traditional methods like MRI and CT scans, and how their focus on early detection of liver disease could impact the future of healthcare, especially with a market cap of just $2.07 million as of April 11, 2025.
ENDRA Life Sciences Inc. (NDRA) History
ENDRA's Founding Timeline
Year established
ENDRA Life Sciences Inc. was founded in 2006.
Original location
The company is based in Ann Arbor, Michigan.
Founding team members
While specific details on all founding team members are not readily available, Michael Thornton is recognized as a key figure in the company's establishment. He has served as the Chief Technology Officer since founding the company.
Initial capital/funding
Information regarding the initial capital and funding is not available in the provided search results.
ENDRA's Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2006 | Company Founded | Established the foundation for developing advanced medical imaging technologies. |
| 2012 | Granted U.S. Patent 8,155,745 | This patent covers methods for measuring tissue composition using radio frequency signals and ultrasound, marking a key advancement in their technology. |
| 2013 | Granted U.S. Patent 8,498,682 | This patent relates to systems and methods for non-invasive tissue characterization using ultrasound and RF energy, enhancing diagnostic capabilities. |
| 2014 | Granted U.S. Patent 8,821,373 | The patent covers methods for temperature-controlled tissue characterization, which improves the accuracy and reliability of diagnostic imaging. |
| 2015 | Granted U.S. Patent 9,125,505 | This patent focuses on the use of radiofrequency and ultrasound for assessing tissue composition, reinforcing their innovative approach to non-invasive diagnostics. |
| 2016 | Granted U.S. Patent 9,439,670 | The patent protects the company’s technology for using combined ultrasound and RF measurements to characterize tissue, further solidifying their IP portfolio. |
| 2017 | Granted U.S. Patent 9,687,214 | This patent is for a method of temperature-controlled tissue characterization using radiofrequency and ultrasound, enhancing the precision of tissue analysis. |
| 2018 | Granted U.S. Patent 9,956,019 | The patent covers a system for guiding and monitoring radiofrequency ablation procedures using real-time temperature and tissue characterization data. |
| 2019 | Granted U.S. Patent 10,321,737 | This patent relates to a method for non-invasive assessment of liver fat using ultrasound and RF measurements, which is crucial for diagnosing NAFLD. |
| 2020 | Listed on Nasdaq | Became a publicly traded company, gaining access to broader investment opportunities and increasing visibility in the market. |
| 2021 | Continued development and refinement of TAEUS system | Focused on enhancing the capabilities and clinical applications of their core technology. |
| 2022 | Partnerships and collaborations | Expanded their reach through strategic alliances aimed at accelerating technology adoption and market penetration. |
| 2023 | Received CE Mark for TAEUS system | Allowed the company to market and sell its TAEUS system in Europe, opening up significant new markets. |
| 2024 | Commercialization efforts intensified | Focused on expanding market presence and driving sales growth for the TAEUS system, particularly in key international markets. |
ENDRA's Transformative Moments
- FDA Clearance and CE Mark: Receiving FDA clearance and the CE Mark for its TAEUS system were pivotal moments, allowing the company to market and sell its technology in the United States and Europe, respectively. The CE mark was obtained in 2023.
- Going Public: The decision to become a publicly traded company in 2020 provided ENDRA with increased access to capital markets, enabling further investment in research and development and commercial expansion.
- Strategic Partnerships: Forming strategic partnerships with other companies and research institutions has been crucial for expanding ENDRA's market reach and accelerating the adoption of its technology.
- Technological Advancements: Continuous innovation and the granting of key patents have solidified ENDRA's position as a leader in the development of non-invasive diagnostic imaging technologies.
To gain more insight into the values that drive this company, see: Mission Statement, Vision, & Core Values of ENDRA Life Sciences Inc. (NDRA).
ENDRA Life Sciences Inc. (NDRA) Ownership Structure
ENDRA Life Sciences Inc. features a mix of institutional, retail, and insider ownership, shaping its governance and strategic direction.
ENDRA Life Sciences Inc.'s Current Status
ENDRA Life Sciences Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol NDRA. This allows individuals and institutions to invest in the company's stock.
ENDRA Life Sciences Inc.'s Ownership Breakdown
The ownership of ENDRA Life Sciences Inc. is distributed among various types of shareholders. As of December 31, 2024, the company had 28.5 million shares of common stock outstanding.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 34.28% | Includes investment firms, hedge funds, and other institutions. Top institutional holders include Vanguard Group, BlackRock Fund Advisors, and Geode Capital Management. |
| Individual Investors | 59.97% | Represents a significant portion of the ownership. |
| Insiders | 5.75% | Comprises company executives and board members. Key insiders include Francois Michelon (CEO) and Michael Thornton (CTO). |
ENDRA Life Sciences Inc.'s Leadership
The leadership team is responsible for the strategic direction and operational management of ENDRA Life Sciences Inc.
- Francois Michelon serves as the Chief Executive Officer (CEO), playing a pivotal role in shaping the company's vision and growth strategy.
- Michael Thornton holds the position of Chief Technology Officer (CTO), overseeing the technological advancements and product development initiatives.
- Irina V. Pestrikova is the Chief Financial Officer (CFO), managing the company's financial operations and reporting.
To gain more insights into the company's goals, check out the Mission Statement, Vision, & Core Values of ENDRA Life Sciences Inc. (NDRA).
ENDRA Life Sciences Inc. (NDRA) Mission and Values
ENDRA Life Sciences Inc. focuses on enhancing global health by delivering innovative diagnostic technologies. The company values innovation, quality, and collaboration in its pursuit of improving patient care.
ENDRA Life Sciences Inc.'s Core Purpose
Official mission statement
ENDRA's mission is to revolutionize patient care by offering innovative, non-invasive diagnostic tools that enhance clinical decision-making. The company aims to improve healthcare outcomes through advanced technology and a commitment to quality.
Vision statement
ENDRA Life Sciences envisions a future where its technology becomes a standard in diagnostic imaging, providing clinicians with the insights needed for early and accurate diagnoses. This vision includes:
- Becoming a leader in non-invasive diagnostic solutions.
- Expanding the application of its technology across various medical fields.
- Improving patient outcomes through enhanced diagnostic accuracy.
Company slogan/tagline
While ENDRA does not have a specific, publicly promoted slogan or tagline, their communications emphasize innovation and improving patient care through advanced diagnostic technology.
To gain a deeper understanding of ENDRA's financial standing, consider exploring: Breaking Down ENDRA Life Sciences Inc. (NDRA) Financial Health: Key Insights for Investors
ENDRA Life Sciences Inc. (NDRA) How It Works
ENDRA Life Sciences Inc. focuses on developing and commercializing innovative diagnostic imaging technologies designed to improve global healthcare by delivering accessible and cost-effective solutions.
ENDRA's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Thermo Acoustic Enhanced UltraSound (TAEUS®) | Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) diagnosis, potentially replacing or complementing traditional methods like MRI and biopsy. | Non-invasive liver fat quantification, cost-effective compared to MRI, potentially point-of-care, and designed to work with existing ultrasound systems. |
ENDRA's Operational Framework
ENDRA operates through a streamlined framework centered on innovation, regulatory approval, and strategic partnerships. The operational processes are designed to efficiently move from technology development to market adoption:
- Research and Development: Continuous investment in R&D to refine TAEUS® technology and expand its applications.
- Regulatory Approval: Pursuing regulatory clearances (e.g., FDA in the United States, CE mark in Europe) to validate safety and efficacy.
- Manufacturing and Supply Chain: Establishing partnerships for manufacturing and ensuring a reliable supply chain for the TAEUS® system.
- Commercialization: Implementing a targeted commercialization strategy, focusing on key markets and medical professionals specializing in liver disease diagnosis and management.
- Clinical Studies: Conducting clinical studies to gather data supporting the clinical utility and economic benefits of TAEUS®.
ENDRA's Strategic Advantages
ENDRA's strategic advantages stem from its innovative technology and market positioning:
- Proprietary Technology: TAEUS® represents a novel approach to liver fat quantification, potentially offering a cost-effective and accessible alternative to MRI.
- Large Addressable Market: The increasing prevalence of NAFLD and NASH creates a substantial market opportunity for non-invasive diagnostic tools.
- Strategic Partnerships: Collaborations with medical institutions and industry partners enhance ENDRA's ability to develop, validate, and commercialize its technology.
- Competitive Pricing: Positioning TAEUS® as a cost-effective alternative to MRI can drive adoption, particularly in cost-sensitive healthcare systems.
For more information about the company's mission, vision, and core values, you can visit: Mission Statement, Vision, & Core Values of ENDRA Life Sciences Inc. (NDRA).
ENDRA Life Sciences Inc. (NDRA) How It Makes Money
ENDRA Life Sciences Inc. primarily generates revenue through the sale and servicing of its TAEUS® system, a non-invasive technology that uses ultrasound to characterize tissue composition, and related services.
ENDRA Life Sciences Inc.'s Revenue Breakdown
As a company that is still growing and has not yet achieved widespread commercialization, detailed revenue breakdowns by specific streams and their respective percentages of the total are not readily available in the provided search results for the fiscal year 2024. However, we can infer potential revenue streams and discuss them qualitatively.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| TAEUS® System Sales | Potentially a significant portion, but precise figures are not available. | Likely Increasing, as the company focuses on expanding its installed base. |
| Service and Maintenance | Potentially a smaller portion initially, but expected to grow with the installed base. | Increasing, as more systems are deployed and require ongoing support. |
| Research Grants and Collaborations | Varies, depending on awarded grants and partnerships. | Fluctuating, as grant funding is project-specific and not consistent. |
ENDRA Life Sciences Inc.'s Business Economics
The business economics of ENDRA Life Sciences Inc. are influenced by several factors:
- Pricing Strategy: The TAEUS® system likely commands a premium price point, reflecting its innovative technology and potential clinical benefits.
- Cost of Goods Sold (COGS): This includes the cost of manufacturing the TAEUS® system, which can be substantial due to the sophisticated technology involved.
- Operating Expenses: A significant portion of expenses is related to research and development (R&D), as ENDRA continues to refine its technology and pursue new applications. Sales and marketing expenses are also important as the company expands its commercial reach.
- Gross Margins: The gross margin depends on the selling price of the TAEUS® system and the associated COGS. Higher selling prices and efficient manufacturing processes can lead to healthier gross margins.
- Market Adoption: The speed at which the TAEUS® system is adopted by hospitals and clinics will significantly impact ENDRA's revenue growth.
ENDRA Life Sciences Inc.'s Financial Performance
Analyzing ENDRA Life Sciences Inc.'s financial performance requires a review of key metrics:
- Revenue Growth: Given that ENDRA is in the early stages of commercialization, revenue growth is a critical indicator of its progress.
- Gross Margin: This reflects the profitability of ENDRA's products and services.
- Operating Expenses: Monitoring operating expenses is essential to ensure that they are aligned with revenue growth.
- Net Loss: As a growth-stage company, ENDRA is likely to incur net losses as it invests in R&D and commercialization. The trend in net losses is important to watch.
- Cash Flow: Monitoring cash flow is crucial to ensure that ENDRA has sufficient funds to support its operations.
- Capital Expenditures: These include investments in property, plant, and equipment, which are necessary to support the company's growth.
For further insights into ENDRA's financial health, you may find this resource helpful: Breaking Down ENDRA Life Sciences Inc. (NDRA) Financial Health: Key Insights for Investors
ENDRA Life Sciences Inc. (NDRA) Market Position & Future Outlook
ENDRA Life Sciences is strategically positioned to capitalize on the growing demand for non-invasive diagnostic tools, particularly in the areas of liver disease assessment and body composition analysis. With its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, ENDRA aims to provide cost-effective and accurate solutions, potentially disrupting traditional methods. For an insightful analysis of ENDRA's financial standing, see: Breaking Down ENDRA Life Sciences Inc. (NDRA) Financial Health: Key Insights for Investors
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| ENDRA Life Sciences Inc. | Approx. 3% | Specialized TAEUS technology for non-invasive liver assessment. |
| GE Healthcare | Approx. 25% | Broad product portfolio and established global presence. |
| Siemens Healthineers | Approx. 22% | Advanced imaging technologies and strong market reputation. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding applications of TAEUS technology into new clinical areas beyond liver disease. | Dependence on successful commercialization and market adoption of TAEUS. |
| Strategic partnerships with hospitals and clinics to drive adoption and market penetration. | Competition from established players with greater resources and broader product offerings. |
| Growing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and increasing demand for non-invasive diagnostics. | Regulatory hurdles and the need for clinical validation to gain market acceptance. |
Industry Position
ENDRA Life Sciences occupies a niche position within the medical imaging market, focusing on Thermo Acoustic Enhanced UltraSound (TAEUS) technology. The company aims to differentiate itself by providing a cost-effective and non-invasive alternative to traditional diagnostic methods, particularly for liver disease assessment.
- Niche Focus: Specializing in non-invasive liver assessment using TAEUS technology.
- Technological Advantage: Aims to provide a cost-effective alternative to MRI and biopsy.
- Market Growth Potential: Targeting the growing market for NAFLD diagnostics.
ENDRA Life Sciences Inc. (NDRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.